ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 102,61
0,83%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pasithea Therapeutics Corporation (KTTA)

  7. Pasithea Therapeutics Corporation (KTTA) Actualités

KTTA

Pasithea Therapeutics (KTTA)

Pasithea Therapeutics Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KTTA
DateHeureSourceTitreSymboleSociété
29/04/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
24/04/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated CancersNASDAQ:KTTAPasithea Therapeutics Corporation
02/03/202403h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
13/02/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
18/01/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTTAPasithea Therapeutics Corporation
08/01/202413h59GlobeNewswire Inc.Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionNASDAQ:KTTAPasithea Therapeutics Corporation
02/01/202414h35GlobeNewswire Inc.Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer PatientsNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323h00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KTTAPasithea Therapeutics Corporation
28/12/202323h00GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023NASDAQ:KTTAPasithea Therapeutics Corporation
19/12/202323h19GlobeNewswire Inc.Pasithea Therapeutics Announces Results from 2023 Annual MeetingNASDAQ:KTTAPasithea Therapeutics Corporation
11/12/202314h01GlobeNewswire Inc.Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft ModelsNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202322h27GlobeNewswire Inc.Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of StockholdersNASDAQ:KTTAPasithea Therapeutics Corporation
29/11/202313h59GlobeNewswire Inc.Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical DevelopmentNASDAQ:KTTAPasithea Therapeutics Corporation
13/11/202322h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KTTAPasithea Therapeutics Corporation
09/11/202313h59GlobeNewswire Inc.Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323h01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KTTAPasithea Therapeutics Corporation
26/10/202323h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
16/10/202323h18Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202315h15Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:KTTAPasithea Therapeutics Corporation
14/09/202314h30GlobeNewswire Inc.Pasithea Therapeutics Corp. Announces Final Results of Tender OfferNASDAQ:KTTAPasithea Therapeutics Corporation
07/09/202322h14GlobeNewswire Inc.Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:KTTAPasithea Therapeutics Corporation
09/08/202315h08Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:KTTAPasithea Therapeutics Corporation
01/08/202313h59GlobeNewswire Inc.Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202315h03Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202314h43GlobeNewswire Inc.Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in CashNASDAQ:KTTAPasithea Therapeutics Corporation
20/07/202314h40GlobeNewswire Inc.Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.NASDAQ:KTTAPasithea Therapeutics Corporation
03/07/202323h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KTTAPasithea Therapeutics Corporation
30/06/202315h28GlobeNewswire Inc.Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of DirectorsNASDAQ:KTTAPasithea Therapeutics Corporation
29/06/202320h50GlobeNewswire Inc.Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp.NASDAQ:KTTAPasithea Therapeutics Corporation
29/06/202314h29GlobeNewswire Inc.Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004NASDAQ:KTTAPasithea Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:KTTA

Dernières Valeurs Consultées

NYSE
HGR
Hanger Orthopedic
COIN
GSAVEBTC
NASDAQ
LBBBW
Lakeshore Acquisition II
COIN
WGRLCETH
Wrapped GRLC
GATE
MQLUSDT
MiraQle
USOTC
YYYH
China Yanyuan Yuhui Nati... (CE)
NYSE
PNI
PIMCO NY Muni Income
AMEX
HEV
COIN
HISCBTC
BIT
F11463
Vontobel Financial Produ...
NASDAQ
ABAHQXX
Royal Bank of Canada Poi...
COIN
ZCLEUR
NASDAQ
AAYLNXX
Royal Bank of Canada Aut...
BIT
F14615
Vontobel Financial Produ...
USOTC
HZLIF
Hertz Energy (QB)
EU
H166S
H166S
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés